Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
3/20/2026, 12:00:00 AM
Biogen and partner Eisai presented new real-world data at the AD/PD™ 2026 conference showing high long-term treatment persistence for LEQEMBI scheduled.
Korean Translation
AD/PD™ 2026 컨퍼런스에서 파트너사 에자이와 함께 레켐비(LEQEMBI)의 장기 치료 지속성이 높다는 새로운 실제 임상 데이터를 발표함. 이는 2026년 3월 20일로 예정됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release is scheduled. High importance estimated due to expected market volatility.
5/13/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Analysts forecast EPS of approximately $0.62 forecasted. Q1 2026 earnings release scheduled. Low impact expected for routine announcement.
5/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q1 2026 earnings release is scheduled for May 5, 2026, with analysts forecasting EPS of approximately $1.27, estimated. Medium importance is estimated as earnings reports typically drive significant price volatility, scheduled.
5/5/2026, 12:00:00 AM